Bionime Corporation (TPE:4737)

Market Cap	3.84B +11.3%
Revenue (ttm)	1.76B -9.5%
Net Income	-247.64M
EPS	-3.59
Shares Out	67.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,089
Open	59.00
Previous Close	59.90
Day's Range	57.10 - 59.00
52-Week Range	50.30 - 73.90
Beta	-0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Bionime

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offers blood glucose monitoring devices and systems under the RIGHTEST brand; a continuous glucose monitoring system under the iFree CGM brand; and medical blood glucose management systems. It is also involved in the prov...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2003
• Employees: 500
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4737

Financial Performance

In 2025, Bionime's revenue was 1.84 billion, a decrease of -4.92% compared to the previous year's 1.93 billion. Losses were -180.28 million, 41.7% more than in 2024.